Electrochemiluminescence immunoassay for the N-terminal pro-B-type natriuretic peptide based on resonance energy transfer between a self-enhanced luminophore composed of silver nanocubes on gold nanoparticles and a metal-organic framework of type MIL-125

Duan, Xue; Zhao, Guanhui; Li, Xuan; Miao, Juncong; Fang, Jinglong; Wei, Qin; Cao, Wei

doi:10.1007/s00604-019-3969-5

Cited by 25 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is the lowest sensitivity value of CLEIA in NT-proBNP detection until now, which can be used for the diagnosis of acute HF. However, the sensitivity of the electrochemiluminescence immunoassay (ECLIA) to NT-proBNP can reach or be even lower than 0.1 ng/L [20,26], which is much lower than that of CLEIA. Although extremely high sensitivity is the most important advantage of ECLIA, the cost of using and maintaining the instrument is very high.…”

Section: Discussionmentioning

confidence: 98%

Development of an NT-ProBNP Assay Reagent Based on High Specific Activity Alkaline Phosphatase CmAP and an Improved Coupling Method

Qiao

et al. 2020

Applied Sciences

View full text Add to dashboard Cite

(1) Background: Chemiluminescent enzyme immunoassay (CLEIA) is an efficient analytical method. Alkaline phosphatase (ALP) with high specific activity is the basis for CLEIA to achieve high sensitivity. In this study, a high specific activity Cobetia marina ALP (CmAP) and an improved coupling method were used to develop an N-terminal pro-B-type natriuretic peptide (NT-proBNP) diagnostic reagent. (2) Methods: The purification method of CmAP was improved and the related enzyme activities were assessed. The enzyme and magnetic beads were coupled only to the Fc region of the detection antibody and the capture antibody, respectively, by using a specially improved method. The NT-proBNP in human serum was assessed. (3) Results: The specific activity of the purified CmAP was found to be 13,133 U/mg. No loss in the enzyme activity was observed after its storage at room temperature for 4 months. The sensitivity of the in vitro diagnostic reagents was found to be 0.58 ng/L. (4) Conclusions: CmAP can be applied as a substitute for the commercial ALP. Analytical parameters indicated that the chemiluminescence diagnostic reagent for NT-proBNP is adequately sensitive and reliable for detecting the serum NT-proBNP, which suggests that both the enzyme and coupling method are suitable for the CLEIA.

show abstract

Section: Discussionmentioning

confidence: 98%

Development of an NT-ProBNP Assay Reagent Based on High Specific Activity Alkaline Phosphatase CmAP and an Improved Coupling Method

Qiao

et al. 2020

Applied Sciences

View full text Add to dashboard Cite

show abstract

“…Because of their large specific surface area, ability to functionalize signal amplification materials, conductivity, and surface charge, luminol-functionalized nanomaterials can address the limitations of conventional luminol and greatly increase strength and sensitivity [88]. Dong et al [89] developed a novel sandwich-style ECL immunoassay to detect NT-proBNP. The method focused on ECL resonance energy transfer (RET) between silver nanocubes covered as the donor by semicarbazide-modified gold NPs (AgNC-sem@AuNPs) and the acceptor is a Ti(IV)-based metal-organic structure of type MIL-125.…”

Section: Nanoparticles For the Early Diagnosis Of Cvdsmentioning

confidence: 99%

Nanodiagnosis and Nanotreatment of Cardiovascular Diseases: An Overview

et al. 2021

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are the world’s leading cause of mortality and represent a large contributor to the costs of medical care. Although tremendous progress has been made for the diagnosis of CVDs, there is an important need for more effective early diagnosis and the design of novel diagnostic methods. The diagnosis of CVDs generally relies on signs and symptoms depending on molecular imaging (MI) or on CVD-associated biomarkers. For early-stage CVDs, however, the reliability, specificity, and accuracy of the analysis is still problematic. Because of their unique chemical and physical properties, nanomaterial systems have been recognized as potential candidates to enhance the functional use of diagnostic instruments. Nanomaterials such as gold nanoparticles, carbon nanotubes, quantum dots, lipids, and polymeric nanoparticles represent novel sources to target CVDs. The special properties of nanomaterials including surface energy and topographies actively enhance the cellular response within CVDs. The availability of newly advanced techniques in nanomaterial science opens new avenues for the targeting of CVDs. The successful application of nanomaterials for CVDs needs a detailed understanding of both the disease and targeting moieties.

show abstract

“…All of these advantages have contributed to intense attention of ECL assay in biomolecule analysis (Hao et al, 2014;Feng et al, 2016). Dong et al (2019) detected NT-proBNP using ECL immunoassay based on ECL resonance energy transfer (RET). The ECL-RET transfer was between semicarbazide-modified Anderon, 2005;Korff et al, 2006;de Jong et al, 2012;Yu et al, 2012;Christenson and Christenson, 2013;Jo et al, 2015 miR-208, miR-208a, miR-208b, miR133, miR-1, miR-133a, miR-21, and miR-499 RNA AMI Upregulated Ji et al, 2009;Corsten et al, 2010;Wang et al, 2010;Gidlöf et al, 2011;Cheng et al, 2012;Long et al, 2012a,b;Oerlemans et al, 2012;Devaux et al, 2013;Friese et al, 2013;Li et al, 2013 miR150, let-7b, and miR-126 RNA AMI Downregulated Devaux et al, 2013;Friese et al, 2013;Li et al, 2013 miR-423, miR-18b, miR-499, miR-142, miR-320a, miR-22, miR-20b, miR-26b, miR-192, miR-194, miR-34a, miR-423-5p, miR320a, miR-22, and miR-92b RNA HF Upregulated Corsten et al, 2010;Tijsen et al, 2010;Goren et al, 2012;Ellis et al, 2013;Marfella et al, 2013;Matsumoto et al, gold nanoparticles (AgNC-sem@AuNPs) covered nanocubes (donor) and a Ti (IV)-based metal-organic framework of type MIL-125 (receptor).…”

Section: Electrochemiluminescence (Ecl) Immunoassaymentioning

confidence: 99%

Section: Fluorescence Immunoassaymentioning

confidence: 99%

Nanoscale Technologies in Highly Sensitive Diagnosis of Cardiovascular Diseases

Shi

Yang

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cardiovascular diseases (CVD) are the leading cause of death and morbidity in the world and are a major contributor to healthcare costs. Although enormous progress has been made in diagnosing CVD, there is an urgent need for more efficient early detection and the development of novel diagnostic tools. Currently, CVD diagnosis relies primarily on clinical symptoms based on molecular imaging (MOI) or biomarkers associated with CVDs. However, sensitivity, specificity, and accuracy of the assay are still challenging for early-stage CVDs. Nanomaterial platform has been identified as a promising candidate for improving the practical usage of diagnostic tools because of their unique physicochemical properties. In this review article, we introduced cardiac biomarkers and imaging techniques that are currently used for CVD diagnosis. We presented the applications of various nanotechnologies on diagnosis within cardiac immunoassays (CIAs) and molecular imaging. We also summarized and compared different cardiac immunoassays based on their sensitivities and working ranges of biomarkers.

show abstract

Electrochemiluminescence immunoassay for the N-terminal pro-B-type natriuretic peptide based on resonance energy transfer between a self-enhanced luminophore composed of silver nanocubes on gold nanoparticles and a metal-organic framework of type MIL-125

Cited by 25 publications

References 41 publications

Development of an NT-ProBNP Assay Reagent Based on High Specific Activity Alkaline Phosphatase CmAP and an Improved Coupling Method

Development of an NT-ProBNP Assay Reagent Based on High Specific Activity Alkaline Phosphatase CmAP and an Improved Coupling Method

Nanodiagnosis and Nanotreatment of Cardiovascular Diseases: An Overview

Nanoscale Technologies in Highly Sensitive Diagnosis of Cardiovascular Diseases

Contact Info

Product

Resources

About